Effect of Body Mass on Filgrastim Pharmacokinetics

Status Completed

Clinical Trial Summary

Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking Neupogen to determine if higher body weights affect drug exposure. The information gathered from this study will help understand if patients with higher body weights need a different dosing plan. Patients in this study will have blood draws once before they take Neupogen and 6 times after they take the Neuopen (for a total of 24 hours). These patients will be in the hospital already and will not need to make additional trips back to have blood drawn. A total of about 5-6 tablespoons of blood will be drawn for this study. 15 obese patients and 15 matched, non-obese patients will be enrolled into this study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01719432
Study type	Observational
Source	West Virginia University
Contact
Status	Completed
Phase
Start date	December 5, 2012
Completion date	December 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02452034` - Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)	Phase 1
Not yet recruiting	`NCT02806557` - Profiling Neutrophil Counts in Patients on Chemotherapy	N/A
Not yet recruiting	`NCT01714557` - Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT01371656` - Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation	Phase 3
Active, not recruiting	`NCT00020865` - Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia	Phase 3
Completed	`NCT00257790` - The Tobramycin Study	Phase 4
Completed	`NCT00020371` - BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy	Phase 1
Terminated	`NCT00005787` - Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00001533` - Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine	Phase 1
Completed	`NCT05585463` - Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
Not yet recruiting	`NCT02238873` - Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma	Phase 3
Completed	`NCT01058993` - AMD 3100 for Treatment of Myelokathexis	Phase 1
Completed	`NCT00771810` - Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer	Phase 2
Completed	`NCT00771433` - G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer	Phase 2
Terminated	`NCT00529282` - A Study of Ceftobiprole in Patients With Fever and Neutropenia.	Phase 3
Completed	`NCT00770172` - G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy	Phase 3
Active, not recruiting	`NCT00030758` - Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer	Phase 4
Completed	`NCT00001790` - Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia	Phase 1
Completed	`NCT00002693` - Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia	Phase 1
Active, not recruiting	`NCT04154488` - A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders	Phase 1/Phase 2